FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-02									

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WESSON BRUCE F					2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC [ACUR]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
												X	Director	Director 10% O			ner	
(Last)	(F	irst)	(Middle)		-								Officer (give title below)			Other (sp below)	ecify	
C/O ACURA PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year)												
					01/04/2016													
616 N. NORTH COURT						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)												Line)				_		
PALATI	NE IL		60067) ×	=	ed by One ed by More	•	ng Person Ine Reporti	ng	
(City)	(S	tate)	(Zip)										Person					
												<i>c</i> · · · ·						
		Та	ble I - Non-	Derivat	ve Se	ecuritie	es Acq	uired,	Disj	oosed of	, or Ben	eficially	Owned					
Date			2. Transacti Date	Execution D			Date, Transaction			es Acquired Of (D) (Instr				6. Ownership Form: Direct		7. Nature of Indirect		
(Month/D					ay/Year) if any (Month/Day/Year)		Code (Instr. 8)				Beneficial Owned Fo		(I) (Instr	str. 4) (Beneficial Dwnership			
										(A) or Price		Reported Transaction(s)				Instr. 4)		
								Code	V	Amount	(D)	Price	(Instr. 3 a					
Common Stock 01/04/				01/04/2	1/2016		M ⁽¹⁾		10,309		(2)	36,64	36,644(3)(4)					
			Table II - D	erivativ	e Sec	urities	Acqu	ired, D	ispo	sed of, o	or Benef	ficially (Owned					
			(€	e.g., put	s, cal	ls, war	rants,	option	ıs, c	onvertib	le secur	ities)						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	e C S Illy D O (I	Downership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
												Amount		(Instr. 4)	011(3)			
												or Number						
				Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	of Shares						
Restricted Stock Units ⁽⁴⁾	(2)	01/04/2016		М			10,309	(5)		(5)	Common Stock	10,309	(2)	0		D		
Restricted Stock Units	(2)	01/04/2016		A		22,026		(6)		(6)	Common Stock	22,026	(7)	22,026	6	D		

Explanation of Responses:

- 1. Represents exchange of restricted stock units.
- 2. Par value of \$.01 must be paid by Reporting Person (or withheld from cash distributions) upon exchange of Restricted Stock Units for cash or stock
- 3. Does not include Restricted Stock Units.
- 4. Reflects 1 for 5 Reverse Stock Split effective August 27, 2015.
- 5. 25% of Restricted Stock Units vested on March 31, 2015, 25% vested on June 30, 2015; 25% vested on September 30, 2015 and 25% vested on December 31, 2015. Restricted Stock Units are being exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value.
- 6. 25% of Restricted Stock Units vest on the last day of each of March, June, September and December 2016. Reporting Person may elect to exchange up to 40% of Restricted Stock Units for cash and the remaining Restricted Stock Units will be exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2017.

7. N/A

Remarks:

<u>/s/ Bruce Wesson</u> <u>01/06/2016</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.